Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) will invest $60m to expand its manufacturing and new drug development activities in Victoria, Australia.
Subscribe to our email newsletter
The company’s Boronia site manufactures sterile and non-sterile liquid products utilizing ‘blow-fill-seal’ (BFS) technology for conditions such as migraine, herpes, epilepsy, smoking cessation, hypertension, asthma, pain relief and anti-virals.
BFS is an advanced antiseptic process which produces a range of container sizes suitable for the delivery of unpreserved, sterile product.
The investment will allow GSK to potentially double its current BFS manufacturing capacity by installing new production technology.
The initiative will also support the formation of a pilot scale industrialization facility for the development of new powder and sterile liquid pharmaceutical products.
The company intends to make this new facility accessible for local companies for contract manufacturing, supporting skills development and technology transfer opportunities for Victorian researchers and companies.
GSK Boronia Site director Troy Webb said with the Victorian Government as a key supporter, this investment will build a sustainable manufacturing capability within the local community while driving manufacturing technology.
The project is anticipated to create 58 new highly-skilled jobs by 2017.
Jake